In this article, we will list the 5 Best Performing American Stocks in June 2026. Please visit 10 Best Performing American Stocks in June 2026 if you would like to see the extended list and the methodology behind it.
Pixabay/Public Domain
5. TG Therapeutics, Inc. (NASDAQ:TGTX)
On July 6, 2026, TG Therapeutics, Inc. (NASDAQ:TGTX) announced the initiation of a Phase 2 clinical trial evaluating Briumvi in adults with treatment-resistant schizophrenia. The open-label study is designed to evaluate the efficacy and safety of Briumvi in approximately 60 adults with schizophrenia who continue to experience significant symptoms despite standard-of-care antipsychotic treatment.
On June 23, Jefferies raised the firm’s price target on TG Therapeutics to $83 from $57 and kept a Buy rating on the shares. Jefferies said the Street “still underappreciates the significance” of Phase 1 subcutaneous Briumvi pharmacokinetic data as predictive of a Phase 3 outcome expected by year-end 2026 to early 2027. Jefferies also updated its model to be more bullish on the subcutaneous opportunity.
On June 9, TG Therapeutics announced topline Phase 1 data for Briumvi in patients with myasthenia gravis and the initiation of a Phase 2 trial evaluating Briumvi as maintenance therapy after induction with efgartigimod. At Week 24, 82% of patients achieved the Minimal Clinically Important Difference in MG-ADL, with a median time to MCID of 30 days, while mean MG-ADL improvement was 4.6 points. The Phase 2 trial is expected to enroll approximately 120 patients, with time to clinical worsening as the primary endpoint.
TG Therapeutics, Inc. (NASDAQ:TGTX) focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
4. CoreCivic, Inc. (NYSE:CXW)
On July 7, 2026, Benchmark raised the firm’s price target on CoreCivic, Inc. (NYSE:CXW) to $41 from $36 and kept a Buy rating on the shares. Benchmark cited CoreCivic’s sale of two California facilities to the U.S. Department of Homeland Security for $1.5B in gross proceeds. The firm said the company is using initial proceeds to eliminate debt and enable share repurchases, while remaining positioned to benefit from potential additional facility sales as DHS continues expanding detention capacity.
On July 6, CoreCivic announced that it completed the sale of its 2,560-bed California City Detention Facility in California City, California, and its 1,994-bed Otay Mesa Detention Center in San Diego, California, to the United States of America and its assigns, through the Department of Homeland Security, for an aggregate gross sales price of $1.5B. CEO Patrick Swindle said the sales demonstrate the value of CoreCivic’s real estate portfolio and provide “significant balance sheet flexibility.”
On June 26, Northland raised the firm’s price target on CoreCivic to $40 from $32 and kept an Outperform rating on the shares. Northland said meetings with security services companies increased its comfort and confidence that the back half of 2026 is positioned to be active. The firm also said timing around the government’s current initiative to acquire private detention facilities remains on track with previous expectations.
CoreCivic, Inc. (NYSE:CXW) owns and operates partnership correctional, detention, and residential reentry facilities in the United States.
3. Dave Inc. (NASDAQ:DAVE)
On July 1, 2026, Benchmark analyst Mark Palmer raised the firm’s price target on Dave Inc. (NASDAQ:DAVE) to $475 from $345 and kept a Buy rating on the shares. Palmer noted that Dave’s share price is up more than 68% year-to-date and said the reasons the stock has decoupled from a fintech group “that the market has spent much of the year selling” are “precisely the reasons” Benchmark believes the stock could have another leg up. Palmer added that the Flex Pay-in-4 card, expected to debut in 2027, should sustain Dave’s momentum.
On June 12, Barrington raised the firm’s price target on Dave to $310 from $290 and kept an Outperform rating on the shares after meeting with management. Barrington said the company’s outlook “remains very positive,” citing Dave’s strategy of acquiring new members, increasing engagement through ExtraCash, and deepening customer relationships with the Dave Card. The firm also said Dave’s large addressable market offers growth opportunities.
On June 10, Dave announced that, effective June 1, 2026, it began transitioning ExtraCash receivables to its strategic funding arrangement with Coastal Community Bank, the wholly owned banking subsidiary of Coastal Financial Corporation (CCB). The arrangement is expected to reduce Dave’s direct funding obligations, lower its cost of capital, and unlock over $200M of liquidity on Dave’s balance sheet once originations are transitioned to Coastal. CEO Jason Wilk called the milestone a “meaningful unlock,” pointing to lower cost of capital, reduced balance sheet exposure, and added liquidity for capital allocation priorities.
Dave Inc. (NASDAQ:DAVE) provides various financial products and services through its financial services platform in the United States.
2. Twist Bioscience Corporation (NASDAQ:TWST)
On July 6, 2026, Evercore ISI downgraded Twist Bioscience Corporation (NASDAQ:TWST) to In Line from Outperform with a price target of $102, up from $66. Evercore ISI said Twist has been one of the best performers in life science tools, up more than 200% year-to-date, with most of the move, or 85%, coming since its May 21 analyst day on optimism around AI-driven order momentum. The firm said it is taking some profits after the rally.
On June 29, Guggenheim raised the firm’s price target on Twist Bioscience to $107 from $60 and kept a Buy rating on the shares. Guggenheim adjusted models and forecasts for select companies in its diagnostics and life sciences tools coverage after meetings with management teams.
On June 24, Barclays analyst Luke Sergott raised the firm’s price target on Twist Bioscience to $95 from $65 and kept an Overweight rating on the shares. Sergott adjusted targets in the life science and diagnostic tools space as part of a Q2 preview, noting that tools are “gaining favor among healthcare subsectors.” Barclays expects in-line to modest beats in Q2 for the group.
Twist Bioscience Corporation (NASDAQ:TWST) manufactures and sells synthetic DNA-based products.
1. SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)
On July 6, 2026, Alliance Global analyst James Molloy raised the firm’s price target on SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) to $25 from $10 and kept a Buy rating on the shares. Molloy said the firm is awaiting the final two deaths in the ongoing Galinpepimut-S Phase 3 REGAL trial in acute myeloid leukemia patients achieving second complete remission. Alliance Global views the delay in top-line data as a potentially significant positive, since it suggests patients may be living longer than anticipated on Best Available Therapy in the CR2 AML setting.
In May, SELLAS reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. CEO Angelos Stergiou said the first quarter marked an “important period” as SELLAS continued executing across clinical programs while preparing for the anticipated pivotal Phase 3 REGAL trial data readout. Stergiou said the upcoming results, triggered by the pre-specified 80th event, will be an “important milestone” for the company. SELLAS said that as of May 11, 2026, 78 events had occurred in the Phase 3 REGAL trial, with the 80th event set to trigger database lock, blinded data review procedures, statistical analysis, unblinding, and disclosure of topline results. The company also initiated an 80-patient Phase 2 trial of SLS009 in newly diagnosed AML patients, with topline data expected in Q4 2026. SELLAS also established an ATM equity offering under its S-3ASR shelf registration, allowing it to raise up to $150 million over time, and said it has not sold any shares through the ATM to date.
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) focuses on the development of novel therapeutics for various cancer indications in the United States.
While we acknowledge the potential of SLS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SLS and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 Fastest Growing Asian Stocks to Buy Now and 12 High Quality Stocks to Buy for the Long Term.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
